Does the introduction of metoprolol increase plasma B-type cardiac natriuretic peptides in patients with mild, stable heart failure?
Clinicians should be aware that introducing metoprolol in mild, stable heart failure causes a rise in BNP/NT-proBNP that is unrelated to clinical deterioration.
Plasma cardiac natriuretic peptide levels increase significantly with the introduction of metoprolol in heart failure as a result of effects on secretion and clearance. Natriuretic responses to NP infusions are sustained with beta-blockade despite reduced renal perfusion pressure. Clinicians should be aware that the introduction of metoprolol causes a rise in plasma BNP/NTproBNP that is unrelated to deterioration in clinical status and must be considered when measurements are undertaken for risk stratification or titration of treatment.
Davis et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: